Suchergebnisse - "Second-generation TKI"

PubPharm (15)

1

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia : A study from the Registro Italiano LMC and Campus CML

enthalten in: Cancer | 2023

von Tiribelli, M. | Latagliata, R. | Breccia, M. | +38

2

A multicenter, open-label, prospective study: Efficacy and safety of double dose of Furmonertinib in patients with initial EGFR-mutation-positive brain metastases NSCLC or EGFR-TKI progression after treatment and EGFR-T790M positive brain metastases NSCLC : A multicenter, open-label, prospective study: Efficacy and safety of double dose of Furmonertinib in patients with initial EGFR-mutation-positive brain metastases NSCLC or EGFR-TKI progression after treatment and EGFR-T790M positive brain metastases NSCLC

enthalten in: WHO International Clinical Trials Registry Platform | 2023

3

A multicenter, open-label, prospective study: Efficacy and safety of double dose of Furmonertinib in patients with initial EGFR-mutation-positive brain metastases NSCLC or EGFR-TKI progression after treatment and EGFR-T790M positive brain metastases NSCLC : A multicenter, open-label, prospective study: Efficacy and safety of double dose of Furmonertinib in patients with initial EGFR-mutation-positive brain metastases NSCLC or EGFR-TKI progression after treatment and EGFR-T790M positive brain metastases NSCLC

enthalten in: WHO International Clinical Trials Registry Platform | 2023

4

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

enthalten in: Pharmaceutical biology | 2021

von Cheng, R. | Huang, Y. | Fang, Y. | +3

5

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

in: Pharmaceutical Biology | 2021

von Rubin Cheng | Yilan Huang | Yun Fang | +3

6

Complexity of chronic-phase CML management after failing a second-generation TKI

enthalten in: Leukemia & lymphoma | 2020

von El Fakih, R. | Chaudhri, N. | Alfraih, F. | +3

7

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives

in: Drug Design, Development and Therapy | 2019

von Lavacchi D | Mazzoni F | Giaccone G

8

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC) : current perspectives

enthalten in: Drug design, development and therapy | 2019

von Lavacchi, D. | Mazzoni, F. | Giaccone, G.

9

Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia

enthalten in: International journal of hematology | 2018

von Fujiwara, S. | Shirato, Y. | Ikeda, T. | +21

10

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations

enthalten in: Internal medicine (Tokyo, Japan) | 2018

von Watanabe, M. | Oizumi, S. | Kiuchi, S. | +4